
Synnovation Therapeutics: Precision oncology firm specializing in small molecule therapies for cancer.
Synnovation Therapeutics, a precision oncology company, was founded with the mission to discover and develop small molecule therapies that target key driver mechanisms in cancer. The company's vision is to transform science and improve lives by creating best-in-class therapeutics for cancer patients. Their market focus is on precision medicine, leveraging deep expertise in cancer biology and medicinal chemistry to build a diverse pipeline of novel small molecules optimized for highly validated disease targets.
Notable affiliated people include a world-class team of experts in medicinal chemistry and cancer biology. Synnovation Therapeutics has attracted significant investment from leading venture capital firms in the biotech sector, underscoring its potential impact. Key achievements include the development of a robust pipeline of promising small molecule therapies. The company's overall impact lies in its commitment to advancing precision oncology, aiming to significantly improve treatment outcomes for cancer patients.

NiKang Therapeutics

Nested Therapeutics
nestedtx.com

Alphina Therapeutics

Nexo Therapeutics
nexotx.com

Traws Pharma

Scorpion Therapeutics

Alterome Therapeutics
alterome.com

Innovo Therapeutics

SynerGene Therapeutics

Odyssey Therapeutics

Window Therapeutics
windowtx.com

Signet Therapeutics

OncoPrecision
oncoprecision.bio

OnCusp Therapeutics
oncusptx.com

OncXerna Therapeutics
oncxerna.com
Companies similar to Synnovation Therapeutics include NiKang Therapeutics, Nested Therapeutics, Alphina Therapeutics and Nexo Therapeutics.
Synnovation Therapeutics was founded in 2021.
Synnovation Therapeutics' headquarters is located in Wilmington, DE, US.
Synnovation Therapeutics' most recent funding round was for $102M (USD) in December 2023.
As of Dec 14, 2023, Synnovation Therapeutics has raised a total of $139M (USD).
Synnovation Therapeutics has 18 employees as of Feb 5, 2024.